BioNTech SE (22UA.F)

EUR 107.0

(-2.28%)

Long Term Debt Summary of BioNTech SE

BioNTech SE's latest annual long term debt in 2023 was 191 Million EUR , up 8.4% from previous year.
BioNTech SE's latest quarterly long term debt in 2024 Q1 was 205.18 Million EUR , up 7.33% from previous quarter.
BioNTech SE reported annual long term debt of 176.2 Million EUR in 2022, up 2.68% from previous year.
BioNTech SE reported annual long term debt of 171.6 Million EUR in 2021, down -25.73% from previous year.
BioNTech SE reported quarterly long term debt of 219.3 Million EUR for 2024 Q2, up 6.98% from previous quarter.
BioNTech SE reported quarterly long term debt of 161.9 Million EUR for 2023 Q3, down -3.11% from previous quarter.

Annual Long Term Debt Chart of BioNTech SE (2023 - 2016)

Historical Annual Long Term Debt of BioNTech SE (2023 - 2016)

Year	Long Term Debt	Long Term Debt Growth
2023	191 Million EUR	8.4%
2022	176.2 Million EUR	2.68%
2021	171.6 Million EUR	-25.73%
2020	231.04 Million EUR	235.32%
2019	68.9 Million EUR	27.09%
2018	54.21 Million EUR	7.68%
2017	50.34 Million EUR	88.79%
2016	26.66 Million EUR	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	205.18 Million EUR	7.33%
2024 Q2	219.3 Million EUR	6.98%
2023 Q3	161.9 Million EUR	-3.11%
2023 FY	191 Million EUR	8.4%
2023 Q2	167.1 Million EUR	-3.07%
2023 Q1	172.4 Million EUR	-2.16%
2023 Q4	191 Million EUR	17.97%
2022 Q4	176.2 Million EUR	-25.65%
2022 FY	176.2 Million EUR	2.68%
2022 Q3	237 Million EUR	14.71%
2022 Q2	206.6 Million EUR	32.95%
2022 Q1	155.4 Million EUR	-9.44%
2021 Q4	171.6 Million EUR	-35.9%
2021 Q1	236.6 Million EUR	4203.38%
2021 Q3	267.7 Million EUR	10.21%
2021 Q2	242.9 Million EUR	2.66%
2021 FY	171.6 Million EUR	-25.73%
2020 Q3	175.62 Million EUR	149.86%
2020 Q1	66.64 Million EUR	-3.28%
2020 FY	231.04 Million EUR	235.32%
2020 Q4	5.49 Million EUR	-96.87%
2020 Q2	70.28 Million EUR	5.47%
2019 Q1	- EUR	-100.0%
2019 FY	68.9 Million EUR	27.09%
2019 Q4	68.9 Million EUR	1.61%
2019 Q2	61.33 Million EUR	0.0%
2019 Q3	67.81 Million EUR	10.57%
2018 FY	54.21 Million EUR	7.68%
2018 Q4	54.21 Million EUR	0.0%
2018 Q1	- EUR	0.0%
2017 FY	50.34 Million EUR	88.79%
2016 FY	26.66 Million EUR	0.0%

Peer Long Term Debt Comparison of BioNTech SE

Name	Long Term Debt	Long Term Debt Difference
CureVac N.V.	36.81 Million EUR	-418.754%
Biotest Aktiengesellschaft	377.3 Million EUR	49.377%
Biotest Aktiengesellschaft	377.3 Million EUR	49.377%
BRAIN Biotech AG	25.19 Million EUR	-658.147%
Formycon AG	7.81 Million EUR	-2344.018%
Heidelberg Pharma AG	70.4 Thousand EUR	-271179.844%
Medigene AG	2.03 Million EUR	-9281.139%